Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04049461
Other study ID # NMU-JSPH-PC-Ossification
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 1, 2019
Est. completion date December 31, 2025

Study information

Verified date August 2019
Source Nanjing Medical University
Contact Jishu Wei, MD,PhD
Phone 086-025-68136891
Email weijishu@njmu.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To investigate whether pancreatic cancer is the cause of heterotopic ossification of abdominal incision.


Description:

Heterotopic ossification of abdominal incision (HOAI) has long been regarded as a rare complication after general surgery. However,according to our retrospective analysis. HOAI was more frequently observed in the malignancy group (33/121 cases, 27.3%) than in the non- malignancy group. Because of the many biases in the retrospective analysis, the result was not widely shared.

The purpose of this prospective study is to confirm that pancreatic cancer is the cause of heterotopic ossification of abdominal incisions. According to postoperative pathology, the patients were divided into two groups: pancreatic cancer group and benign diseases group.The researchers will observe whether patients develop heterotopic ossification of the abdominal incision one year after surgery to conclude.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 105
Est. completion date December 31, 2025
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Obtain informed consent from the patients.

- The patient's abdominal incision was double-closed with continuous suture of linea alba and fascia with absorbable suture, and skin was sutured with skin staples.

Exclusion Criteria:

- Refusing to join the study

- Previous history of malignant tumor

- Previous history of midabdominal incision

- Abnormal calcium and phosphorus metabolism

- Distant metastasis

- Palliative operation

- performing neoadjuvant chemotherapy

Study Design


Intervention

Diagnostic Test:
Bone alkaline phosphatase
Hematologic indicators reflecting ossification.
Radiation:
Abdominal CT scan
Observe whether HOAI occurs.

Locations

Country Name City State
China The first affiliated hospital of Nanjing Medical University Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Nanjing Medical University

Country where clinical trial is conducted

China, 

References & Publications (5)

Citak M, Grasmücke D, Suero EM, Cruciger O, Meindl R, Schildhauer TA, Aach M. The roles of serum alkaline and bone alkaline phosphatase levels in predicting heterotopic ossification following spinal cord injury. Spinal Cord. 2016 May;54(5):368-70. doi: 10.1038/sc.2015.211. Epub 2015 Dec 8. — View Citation

Ghuman MS, Saggar K. Images in clinical medicine. Heterotopic ossification of a midline abdominal incision. N Engl J Med. 2014 Jul 31;371(5):464. doi: 10.1056/NEJMicm1312006. — View Citation

Isaacson BM, Potter BK, Bloebaum RD, Epperson RT, Kawaguchi BS, Swanson TM, Pasquina PF. Link Between Clinical Predictors of Heterotopic Ossification and Histological Analysis in Combat-Injured Service Members. J Bone Joint Surg Am. 2016 Apr 20;98(8):647-57. doi: 10.2106/JBJS.15.00895. — View Citation

Kim J, Kim Y, Jeong WK, Song SY, Cho OK. Heterotopic ossification developing in surgical incisions of the abdomen: analysis of its incidence and possible factors associated with its development. J Comput Assist Tomogr. 2008 Nov-Dec;32(6):872-6. doi: 10.1097/RCT.0b013e318159c617. — View Citation

Koolen PG, Schreinemacher MH, Peppelenbosch AG. Heterotopic ossifications in midline abdominal scars: a critical review of the literature. Eur J Vasc Endovasc Surg. 2010 Aug;40(2):155-9. doi: 10.1016/j.ejvs.2010.03.010. Epub 2010 Apr 18. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Overall survival Patients with pancreatic cancer were divided into HOAI and non-HOAI groups to determine whether there were differences between the OS of two groups. 5 years
Primary Incidence of HOAI HOAI is determined by CT, whose CT number is similar to that of the same spine. 12 months
Primary Bone alkaline phosphatase Preoperative tests were performed and every three months postoperatively 12 months
Secondary Incidence of distant metastasis and local recurrence Patients with pancreatic cancer were divided into HOAI and non-HOAI groups to determine whether there were differences in the incidence of distant metastasis and local recurrence between the two groups. 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02902484 - Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT04008537 - Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device N/A
Recruiting NCT04809935 - EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy Phase 4
Not yet recruiting NCT03659292 - Effects of Epidural Block on the Prognosis in Patients With Pancreatic Cancer Undergoing Distal Pancreatectomy N/A
Completed NCT03150615 - Enteral Nutrition After Pancreaticoduodenectomy N/A
Recruiting NCT02682394 - Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas N/A
Recruiting NCT05566743 - A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas Phase 2
Recruiting NCT04164602 - The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
Active, not recruiting NCT04128332 - Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer N/A
Recruiting NCT03536793 - Tumour Regulatory Molecules in Early Pancreatic Cancer Detection
Recruiting NCT02311439 - Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas Phase 2/Phase 3
Completed NCT02296736 - The Pre-operative Pathway in Pancreatic Head Malignancy-assessment of the Diagnostic Accuracy of Staging CT Scan
Withdrawn NCT04123574 - A Pilot Study of BXCL701 in Patients With Pancreatic Cancer Early Phase 1
Not yet recruiting NCT03278015 - Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT02905578 - A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) Phase 2
Completed NCT01446458 - Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer Phase 1
Recruiting NCT04677244 - Echo-endoscopy Biopsy Impact on the Circulating Tumor Cell Level N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT06148298 - Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer
Terminated NCT03451773 - M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas Phase 1/Phase 2